My Agios | Home

myAgios™ Patient Support Services is a program that helps with access and financial assistance

myAgios™ Patient Support Services for TIBSOVO® include:

  • Support with insurance coverage and reimbursement
  • Financial assistance and coverage support programs to help patients with access to TIBSOVO
  • Prescription fulfillment through our network of specialty pharmacies and distributors
To enroll patients in myAgios™, visit myagios.com or call 1‑844‑409‑1141, Monday through Friday, 8 AM to 6 PM ET

Ordering and distribution network

National Drug Code (NDC)

NDCs Dosage strength Description
10-digit code: 72694-617-60
11-digit code: 72694-0617-60
250 mg/tablet 250-mg tablet: Blue oval-shaped film-coated tablet debossed “IVO” on one side and “250” on the other side
The red zero converts the 10-digit NDC to the 11-digit NDC. Some payers may require each NDC to be listed on the claim. Payer requirements regarding the use of NDCs may vary. Electronic data exchange generally requires use of the 11-digit NDC.

Product information

How TIBSOVO is supplied: 250-mg tablets, supplied in 60-count bottles (30-day supply) with a desiccant canister

Storage: Store at 20 to 25 ºC (68 to 77 ºF)

TIBSOVO® Bottle

Distribution network for TIBSOVO

TIBSOVO is only available through our specialty distributors and network specialty pharmacies.

Specialty distributors: TIBSOVO is available through specialty distributors for shipment directly to office- or hospital-based pharmacies.
Network specialty pharmacies: TIBSOVO ships directly from the specialty pharmacy to your patient’s home or preferred location.

TIBSOVO resources for your patients and their caregivers

These resources may be useful to patients and caregivers throughout treatment with TIBSOVO

TIBSOVO resources for you and your practice

Educational videos

Learn about a targeted approach to treating newly diagnosed and R/R AML with IDH1 mutations

Watch the interview with Dr. Gary Schiller,
MD, FACP

INTRODUCTION

Learn about a targeted approach to treating R/R AML with IDH1 mutations

Watch the interview with Dr. Muthu Veeraphuthiran, MD, MPH, FACP

INTRODUCTION

Some participants in these videos are current or former employees of Agios or Servier.

Please see Full Prescribing Information, including BOXED WARNING.

Welcome to Target: AML—a podcast series from TIBSOVO

Target: AML is a podcast all about TIBSOVO and AML—from discussing the disease to uncovering the challenges and rewards of treating patients.

Episode 1: Jonathan Abbas, MD & Mark Levis, MD, PhD

On this episode of Target: AML, Jonathan Abbas, MD, and Mark Levis, MD, PhD, discuss the challenges and rewards of treating R/R mIDH1 AML.

 
 

INDICATIONS

TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with a susceptible IDH1 mutation as detected by an FDA-approved test with:

Acute Myeloid Leukemia (AML)

  • Newly-diagnosed AML who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
  • Relapsed or refractory AML.
Indications & Important Safety Information

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME IN AML

Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

more